CRI Logo
  • About
    • Impact
    • History
    • Team
    • Careers
    • Blog
    • Media Room
  • What is Immunotherapy?
    • Immunotherapy Basics
    • Treatment Types
    • Cancer Types
    • Side Effects
  • Patient Support
    • Patient Resources
    • Clinical Trials
    • Immunotherapy Stories
    • Connect with ImmunoAdvocates
  • Grants & Research Programs
    • Apply for Grants
    • Research Programs
    • Clinical Programs
    • Data Programs
    • CRI Funded Scientists
  • Get Involved
    • Ways to give
    • Fundraise
    • Events
    • Partnership
    • Contact
Donate

Immune to Cancer: The CRI Blog

  • TJ Sharpe

    T.J. Sharpe’s Immunotherapy Story

    Melanoma |  Diagnosed 2012 When I was in the hospital, I made a vow that when I was…
    March 14, 2017| CRI Staff
  • Karen Koehler

    Karen Koehler’s Immunotherapy Story

    Leukemia |  Diagnosed 2011 It was brutal, but I was prepared…I bounced back very quickly. Karen’s Story When…
    March 14, 2017| CRI Staff
  • John Deisher

    Jon Deisher’s Immunotherapy Story

    Esophageal Cancer |  Diagnosed 2013 Jon’s Story Jon Deisher is a life-long Alaskan who has devoted himself to…
    March 14, 2017| CRI Staff
  • Ann Silberman

    Ann Silberman’s Immunotherapy Story

    Breast Cancer | Diagnosed 2009 You learn to see life in a different way when you know…
    March 14, 2017| CRI Staff
  • Colorectal Cancer Awareness Month: How Immunotherapy Offers Hope for the Future

    March is Colorectal Cancer Awareness Month, and the need for a spotlight on this disease is as…

    March 8, 2017| Arthur N. Brodsky, PhD
  • Meet Tecla: 50-Mile Rider in the 2017 Answer to Cancer

    For Tecla Palli-Sandler, participating in the 2017 Answer to Cancer Cycling Event and 5K Family…

    February 24, 2017| Katherine McCluskey
  • New Biomarker ‘Bim’ Could Enable Smarter Treatment for Melanoma Patients

    Over the past few years, checkpoint blockade immunotherapies have revolutionized cancer treatment and helped many patients who…

    February 22, 2017| Arthur N. Brodsky, PhD
  • Third Immunotherapy Option Approved for Bladder Cancer Patients

    On February 2, nivolumab (Opdivo®, Bristol-Myers Squibb) became the newest FDA-approved immunotherapy available for patients with bladder…

    February 8, 2017| Arthur N. Brodsky, PhD
  • Immunotherapy Shows Promise Against Previously Untreatable Stomach Cancer

    Nivolumab improves survival in patients with advanced stomach cancer.

    February 3, 2017| Arthur N. Brodsky, PhD
Previous Page
1 … 64 65 66 67 68 … 92
Next Page
Father and son

Join CRI in Shaping the Future of Immunotherapy

Support the pioneering work of CRI in advancing immunotherapy.

See ways to give

Cancer Research Institute
29 Broadway, Floor 4

New York, NY  10006-3111

Facebook Icon
X icon
YouTube icon
LinkedIn icon
Instagram icon
Threads icon
  • About
    • Impact
    • History
    • Team
    • Careers
    • Blog
    • Media Room
  • What is Immunotherapy?
    • Immunotherapy Basics
    • Treatment Type
    • Cancer Type
    • Side Effects
  • Patient Support
    • Patient Resources
    • Clinical Trials
    • Immunotherapy Stories
    • Connect with ImmunoAdvocates
  • Grants & Research Programs
    • Apply for Grants
    • Research Programs
    • Clinical Programs
    • Data Programs
    • CRI Funded Scientists
  • Get Involved
    • Donate
    • Ways to give
    • Fundraise
    • Events
    • Partnership
    • Contact

Uniting for a World Immune to Cancer

  • Accessibility Statement
  • Privacy Policy
  • Terms & Conditions
  • Site Map

*Immunotherapy results may vary from patient to patient.

©2025, Cancer Research Institute